Nephrotoxicity From Molecularly Targeted Chemotherapeutic Agents

Kala, Jaya; Salman, Liann Abu; Geara, Abdallah S.; Izzedine, Hassan

doi:10.1053/j.ackd.2021.09.003

Cited by 7 publications

(8 citation statements)

References 162 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This issue can result in increased proteinuria and the development of thrombotic microangiopathy (TMA) [ 29 , 36 , 37 ]. Additionally, REG, like other well-documented anti-angiogenetic agents, may exhibit dose-dependent nephrotoxicity [ 38 ]. Moreover, renal impairment has been associated with BRAFi, including ENC.…”

Section: Discussionmentioning

confidence: 99%

“…Patients with cancer often experience a lower health-related QoL, which can be influenced by the use of chemotherapeutic agents, including second- and third-line therapies, as previously observed [ 53 , 54 ]. Notably, the increased use of TKIs as a second-line therapy in patients with mCRC following prior treatment with nephrotoxic chemotherapeutic agents may impact QoL [ 28 , 38 , 55 , 56 ]. Moreover, renal disorders can worsen over the duration of the tumor course and the progression of metastases.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System Database

Russo,

Barbieri,

Sorbara

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Background: this study assessed the nephrotoxicity of regorafenib (REG) and encorafenib (ENC) in metastatic colorectal cancer (mCRC) through an analysis of reports from the US Food and Drug Administration’s Adverse Event Reporting System (FAERS) database. Methods: descriptive and disproportional analyses were performed for all reports using ENC and REG as the primary suspect. Results: A total of 379 reports had at least one renal adverse drug reaction (ADR), and these ADRs were mainly related to REG (93.1%). Potential safety signals for REG included chromaturia (n = 44; ROR = 12.00, CI 95% = 8.92–16.16; IC = 2.36, IC025–IC075 = 2.06–2.66), hydronephrosis (10; 8.70, 4.67–16.19; 1.85, 1.23–2.47), nephrotic syndrome (7; 5.73, 2.73–12.03; 1.47, 0.73–2.21), renal impairment (53; 4.16, 3.17–5.45; 1.39, 1.12–1.66), dysuria (19; 3.06, 1.95–4.81; 1.06, 0.61–1.52), renal failure (38; 1.66, 1.20–2.28; 0.49, 0.17–0.81), and acute kidney injury (AKI) (43; 1.46, 1.08–1.97; 0.37, 0.07–0.67). For ENC, consistent disproportionalities were observed for AKI (n = 11; ROR = 3.79, CI 95% = 2.09–6.90; IC = 1.32, IC025–IC075 = 0.72–1.91) and dysuria (4; 6.50, 2.43–17.39; 1.86, 0.88–2.85). Conclusions: these findings highlight some not extensively reported renal ADRs that require further investigations to better characterize the safety profiles of REG and ENC in patients with mCRC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System Database

Russo,

Barbieri,

Sorbara

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Megjegyzés: Összefoglalónk alapját az alább is hivatkozott, 2021-ben az Advances in Chronic Kidney Disease folyóiratban megjelent cikksorozat egyes részei képezték (3,4,9,16,24,25).…”

Section: Car-t-sejt Terápiaunclassified

“…A nefron és a molekuláris célpontok elhelyezkedése a vesében. A nephrotoxicus hatás a gátolt célmolekulától függ(16)…”

unclassified

Onkonefrológiai kitekintő

Várady¹,

Szlovák²,

Dolgos³

2022

Hypertonia és Nephrologia

View full text Add to dashboard Cite

A daganatos betegek kezelésében elért áttörő eredmények okozta javuló életkilátás és hosszabb túlélés miatt egyre nagyobb jelentőségű az új típusú gyógyszeres onkoterápiák kapcsán kialakuló rövid és hosszú távú szövődmények, mellékhatások pontosabb megismerése. A daganatos betegek kezelése során a kemoterápiát követően kialakuló két leggyakoribb életveszélyes szövődmény az akut veseelégtelenség (AVE) és a tumorlízis-szindróma (TLS), amely miatt minden esetben nefrológus bevonása szükséges. Az onkológiai terápiás paletta szélesedésével egyre szerteágazóbb nephrotoxicus mellékhatásprofillal kell számolnunk. Jelenleg még mindig a konvencionális kemoterápiák a leggyakrabban alkalmazott tumorellenes terápiák, ezért ezen gyógyszerek használatával kapcsolatos veseszövődmények megismerése és megelőzési lehetőségeinek ismerete kiemelkedő jelentőségű, azonban az új típusú immunterápiák és a molekulárisan célzott terápiák eddig ismeretlen mechanizmusú mellékhatásaival és nephrotoxicus hatásával is számolnunk kell a mindennapi klinikai gyakorlatban. Ezáltal a multidiszciplináris megközelítést igénylő onkológiai gondozás során a nefrológusok is egyre nagyobb szerepet kapnak, így egy új szubspecialitás, a klinikai onkonefrológia megjelenése figyelhető meg.

show abstract

“…Molecularly targeted therapy involves using drugs or other substances that speci cally target certain molecules (molecular targets) to inhibit the growth and spread of cancer cells [9]. This treatment approach offers advantages such as precise and e cient drug delivery, as well as reduced toxicity compared to traditional chemotherapy drugs, which improves the survival rate of many types of malignant tumors [10]. While signi cant progress has been made in the systemic treatment of advanced NSCLC through molecular targeted therapy and immunotherapy, the long-term survival rate for lung cancer patients remains low [11][12][13].…”

Section: Introductionmentioning

confidence: 99%

High expression of ISG20L2 promotes proliferation and invasion of A549 cells and is associated with poor prognosis in lung adenocarcinoma

Zhang,

Yu,

Liu

2024

Preprint

View full text Add to dashboard Cite

Background Interferon-stimulated 20kDa exonuclease-like 2 (ISG20L2) is a gene that exhibits differential expression in lung adenocarcinoma (LUAD). However, its expression and function in LUAD remain poorly understood. The aim of this study was to investigate the expression of ISG20L2 in LUAD and its correlation with prognosis, as well as to explore its impact on the biological behavior of LUAD. Methods The researchers analyzed the expression of ISG20L2 using both The Cancer Genome Atlas (TCGA) database and immunohistochemistry (IHC). Enrichment analysis was performed using the "GOplot" and "clusterprofile" R packages. The correlation between ISG20L2 expression and prognosis of LUAD patients was assessed through IHC and Kaplan-Meier survival analysis. Additionally, the diagnostic value of ISG20L2 in LUAD was evaluated using ROC curve analysis. The relationship between ISG20L2 expression and clinicopathological characteristics was examined through IHC. Overexpression and knockout experiments of ISG20L2 were conducted via transient transfection. The biological properties of ISG20L2 in A549 cells, including cell proliferation, apoptosis, migration, and invasion abilities, were investigated using assays such as cell counting kit-8 (CCK-8), flow cytometry, and Transwell assays. Results The findings indicated that ISG20L2 was highly expressed in LUAD, and its high expression was closely associated with poor prognosis. In vitro experiments further confirmed a positive correlation between ISG20L2 expression level and the proliferation, migration, and invasion abilities of LUAD cells, while no significant effect on apoptotic ability was observed. Conclusion Our study indicates that ISG20L2 promotes the proliferation, migration, and invasion of LUAD cells, and its high expression predicts a poorer prognosis for LUAD patients. This study suggests that ISG20L2 has the potential to serve as a molecular marker for the treatment and prognosis of LUAD.

show abstract

Nephrotoxicity From Molecularly Targeted Chemotherapeutic Agents

Cited by 7 publications

References 162 publications

Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System Database

Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System Database

Onkonefrológiai kitekintő

High expression of ISG20L2 promotes proliferation and invasion of A549 cells and is associated with poor prognosis in lung adenocarcinoma

Contact Info

Product

Resources

About